Subsequently, we conducted flow cytometric analyses on murine tumour tissues, which further confirmed that after treatment with anlotinib, there was a significant increase in the proportion of PD‐1 positive expression among CD8+ T cells (Anlotinib vs. NC, p < 0.01; Anlotinib + anti‐PD‐1 vs. This evidence concerns the gene CD8A and neoplasm.